Scientists develop new ways of understanding cardiovascular disease and creating new medications, treatments, and devices through research and testing these new medications, treatments, and devices in clinical trials. One of the most respected centers in cardiovascular research, Lenox Hill Heart and Vascular Institute (LHHVI) is a leader in clinical research.
LHHVI researchers have been at the forefront of the treatment of cardiovascular disease, and LHHVI is the first center in the United States to perform an angiogram, coronary angioplasty, minimally invasive coronary artery bypass graft surgery, and drug-coated (drug-eluting) stent implantation.
Although LHHVI researchers participate in clinical trials involving all aspects of cardiovascular disease, they have achieved particular notoriety in the development of techniques to open blockages in coronary and peripheral arteries and prevent their reoccurrence, including the use of drug-eluting stents to prevent re-blockage (restenosis) in arteries and carotid stenting for the carotid arteries (the arteries in the neck that feed the brain). These studies are often national multi-center trials, which allows LHHVI researchers to work with the best minds in the country (and often the world) to tackle the toughest problems regarding the treatment of cardiovascular disease.
Our participation in groundbreaking research contributes to the advancement of cardiovascular care in general, and it also means that we can quickly adopt the latest advances and bring them to our patients.
